Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems

H Hadji, K Bouchemal - Advanced Drug Delivery Reviews, 2022 - Elsevier
The complex pathogenesis of inflammatory bowel disease (IBD) explains the several
hurdles for finding an efficient approach to cure it. Nowadays, therapeutic protocols aim to …

Animal models for the investigation of P2X7 receptors

R Sluyter, S Adriouch, SJ Fuller, A Nicke… - International Journal of …, 2023 - mdpi.com
The P2X7 receptor is a trimeric ligand-gated cation channel activated by extracellular
adenosine 5′-triphosphate. The study of animals has greatly advanced the investigation of …

Purinergic signalling in graft-versus-host disease

R Sluyter, P Cuthbertson, A Elhage, C Sligar… - Current Opinion in …, 2023 - Elsevier
Allogeneic hematopoietic stem cell transplantation is used to treat blood cancers, but often
results in lethal graft-versus-host disease (GVHD). GVHD is an inflammatory disorder …

Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation

TBD McEwan, RA Sophocleous, P Cuthbertson… - Life Sciences, 2021 - Elsevier
Aims Application of exogenous nucleotides can modulate wound healing via the activation
of purinergic receptors. However, evidence for the release of endogenous nucleotides and …

Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐versus‐host disease development in humanized mice treated with post …

C Sligar, P Cuthbertson, NA Miles… - … and Cell Biology, 2023 - Wiley Online Library
Graft‐versus‐host disease (GVHD) is a life‐threatening complication following donor
hematopoietic stem cell transplantation, where donor T cells damage host tissues. This …

A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice

A Elhage, P Cuthbertson, C Sligar, D Watson, R Sluyter - Pharmaceutics, 2023 - mdpi.com
Graft-versus-host disease (GVHD) is a T cell-mediated inflammatory disorder that arises
from allogeneic haematopoietic stem cell transplantation and is often fatal. The P2X7 …

P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model

P Cuthbertson, NJ Geraghty, SR Adhikary… - Clinical …, 2021 - portlandpress.com
Graft-versus-host disease (GVHD) is a severe inflammatory response arising from
allogeneic haematopoietic stem cell transplantation. Previous studies revealed that …

Recent metabolic advances for preventing and treating acute and chronic graft versus host disease

FA Mohamed, G Thangavelu, SY Rhee… - Frontiers in …, 2021 - frontiersin.org
The therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
limited by the development of graft-versus-host disease (GVHD). In GVHD, rigorous pre …

Purinergic signalling in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease

P Cuthbertson, NJ Geraghty, SR Adhikary… - International Journal of …, 2021 - mdpi.com
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for
blood cancers and other haematological disorders. However, allo-HSCT leads to graft …

P2X7 receptor in hematological malignancies

E De Marchi, A Pegoraro, E Adinolfi - Frontiers in Cell and …, 2021 - frontiersin.org
The P2X7 receptor is an ion channel gated by the nucleotide ATP, known for its role in
immune responses and recently emerging as a critical onco-promoting factor. Lymphocytes …